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Abstract: Parallel advancements in surgical technique, preoperative and postoperative care, as well as a better under-
standing of physiology in patients with duct-dependent pulmonary or systemic circulation and a functional single ventri-
cle, have led to superb results in staged palliation of most complex congenital heart disease (CHD) [1]. The Fontan proce-
dure and its technical modifications have resulted in markedly improved outcomes of patients with single ventricle anat-
omy [2,3,4]. The improved early survival has led to an exponential increase of the proportion of Fontan patients surviving 
long into adolescence and young adulthood [5]. Improved early and late survival has not yet abolished late mortality sec-
ondary to myocardial failure, therefore increasing the referrals for cardiac transplantation [6]. Interstage attrition [7] is 
moreover expected in staged palliation towards completion of a Fontan-type circulation, while Fontan failure represents a 
growing indication for heart transplantation [8]. Heart transplantation has therefore become the potential “fourth stage” [9] 
or a possible alternative to a high-risk Fontan operation [10] in a strategy of staged palliation for single ventricle physiol-
ogy. Heart transplant barely accounts for 16% of pediatric solid organ transplants [11]. The thirteenth official pediatric 
heart transplantation report- 2010 [11] indicates that pediatric recipients received only 12.5% of the total reported heart 
transplants worldwide. Congenital heart disease is not only the most common recipient diagnosis, but also the most pow-
erful predictor of 1-year mortality after OHT. Results of orthotopic heart transplantations (OHT) for failing single ventri-
cle physiology are mixed. Some authors advocate excellent early and mid-term survival after OHT for failing Fontan [9], 
while others suggest that rescue-OHT after failing Fontan seems unwarranted [10]. Moreover, OHT outcome appears to 
be different according to the surgical staging towards the Fontan operation and surgical technique of Fontan completion 
[12]. 
The focus of this report is a complete review of the recent literature on OHT for failing single ventricles, outlining the 
clinical issues affecting Fontan failure, OHT listing and OHT outcome. These data are endorsed reporting our experience 
with OHT for failing single ventricle physiology in recent years.  
Keywords: Pediatric heart transplantation, fontan failure, univertricular physiology. 
BACKGROUND 
  Neonatal palliation and staged reconstruction towards a 
Fontan-type circulation is currently feasible in most patients 
with complex CHD and single ventricle physiology. The 
concept of Fontan staging through a hemifontan or a bidirec-
tional Genn shunting (BDG) has reduced the early mortality 
for Fontan completion, preventing the onset of diastolic ven-
tricular dysfunction [13]. Recent publications report a 10 
year survival after extracardiac Fontan completion varying 
between 85% and 93%. [2,3,4] . A recent large multicenter 
study on 321 patients who survived Fontan completion re-
ported a 5-year transplant-free survival of 86% [14]. Techni-
cal evolution towards total cavopulmonary connection and 
the introduction of the fenestration concept have resulted in 
extended indication for the modified Fontan operation. Nev-
ertheless interstage attrition prior to Fontan completion and 
relaxed Fontan criteria can result in early failure of a Fontan 
circuit [15]. Aside from the experience of Bailey [16], heart 
transplantation is usually considered as “the last resource” in 
the decision-making process, with a strong focus on the 
preservation of the native myocardium. Even in the ideal 
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Fontan candidate, however, the instantaneous risk of death 
from cardiac failure progressively increases two years from 
surgery [17] and a steady decline in survival is documented 
between 5 and 7 years after Fontan completion [15].The at-
trition rate is known to be highest within the first six months 
after Fontan completion, but protein-losing enteropathy 
(PLE)[18], plastic bronchitis [19], arrhythmias, or progres-
sive cardiac failure [15] can occur as potentially fatal com-
plications of the Fontan procedures. Current evidence sug-
gests that progressive alterations in the structure and function 
of the pulmonary vasculature may play a pivotal role in late 
Fontan failures [20]. Therefore single ventricle circulation 
appears to have a limited durability per se and myocardial 
dysfunction or failure/intolerance of Fontan physiology rep-
resent a growing indication for heart transplantation. Patients 
with single ventricle physiology are predicted to represent 
70% to 80% of patients transplanted for congenital heart 
disease [21] in the near future The worldwide number of 
pediatric heart transplants has increased in recent years from 
an average of 384 OHT/year in the 1990s, to 428/year 
through the 2000s; in 2008, 491 pediatric heart transplants 
were reported to the Registry. Yet limited donor supply re-
mains the major drawback, especially for small size recipi-
ents. The 13
th annual report report of the ISHLT [11] demon-
strated a consistent and substantial improvement in Kaplan 
Meier survival over the last 2 decades, with a 65% 10-year 86    Current Cardiology Reviews, 2011, Vol. 7, No. 2  Michielon et al. 
survival for patients under 10 years of age. Nevertheless 
CHD still represents the leading independent predictor of 1-
year mortality after pediatric heart transplantation, doubling 
the risk of death of OHT for non-congenital diagnosis. This 
occurs while 63% of OHT in infancy are accomplished on 
patients with CHD. Therefore, the issue is twofold. On one 
side CHD still represents an important independent predictor 
of mortality after OHT, and failing single ventricle is the 
most complex subgroup of CHD requiring OHT. On the 
other side there is a growing need for heart transplantation 
for failing single ventricles. Yet all transplant candidates 
compete for the same donor pool, forcing the ethical issue of 
making the best use of a limited resource. The efficacy of 
OHT as a therapeutic option for failing single ventricles 
should ultimately consider two important points: modality of 
Fontan failure as an indication for OHT and optimal surgical 
staging of single ventricles towards Fontan completion ver-
sus heart transplantation.  
MODALITIES OF FONTAN FAILURE 
  The Fontan circulation is based upon two fundamentals: 
adequate systolic/diastolic function of the single ventricle 
and unobstructed pulmonary pathway. The multifactorial 
mechanisms that contribute to Fontan failure undermine 
these two cornerstones for a successful Fontan palliation, 
nevertheless some are potentially correctable [22]. Primary 
palliative procedures strategy has a profound effect on both 
early and late success of Fontan circulation. Failure to pro-
vide early protection of the pulmonary vascular bed, delay in 
reducing volume loading of the single ventricle (systemic-to-
pulmonary shunts, aorto-pulmonary collaterals), onset of 
atrioventricular or semilunar valve incompetence, do con-
tribute to ventricular dysfunction, ultimately impacting Fon-
tan outcome [23]. In addition, the Fontan circulation per se 
results in a chronically underloaded ventricle, following pri-
mary volume-loading palliative procedures [24,25]. The se-
quence of volume-loading followed by volume-unloading 
procedures promotes diastolic dysfunction, which can be 
worsened by any mechanism inducing ventricular hypertro-
phy, like new or recurrent obstructions in the systemic arte-
rial pathway (i.e. sub-aortic stenosis, re-coarctation). Other 
failure mechanisms can result from anatomic substrates like 
heterotaxy [26,27] and especially asplenia syndrome, from 
anatomic lesions like stenosis in the pulmonary arterial 
pathway or pulmonary venous obstruction, or physiologic 
inefficiency of the Fontan pathway secondary to arrhyth-
mias, like loss of sinus rhythm or atrial tachyarrhythmias. 
Most of these anatomic and physiologic drawbacks are po-
tentially correctable [28] with Fontan revision [29], valve 
repair, pacing or catheter-based interventions, with the ulti-
mate goal of preserving systolic and diastolic function of the 
single ventricle, while minimizing energy loss throughout 
the arterial and venous pulmonary pathway. 
  Conversely, other failure mechanisms are intrinsically 
related to the Fontan circulation itself, which sets the pulmo-
nary capillary bed in series with the systemic, splanchnic and 
hepatic capillary bed, rendering the state of the pulmonary 
vascular bed critical to the Fontan circulation. Even mild 
increases in pulmonary vascular resistance are likely to have 
a negative impact on Fontan longevity. The underlying 
mechanism behind increased PVR in Fontan patients is not 
completely clear. Pulsatile pulmonary blood flow in normal 
hearts plays an important role in the reduction of PVR by 
passive capillary recruitment. When cardiac output increases, 
as in response to exercise, previously underperfused pulmo-
nary vessels are recruited, thereby responding to increase in 
flow demand by decreasing PVR, resulting in a small in-
crease in mean PAP relative to the increase in cardiac output. 
In the normal circulation most of the energy transmitted to 
the pulmonary arterial bed by right ventricular ejection is 
therefore committed to maintain patency of the distal pulmo-
nary vascular bed [30]. In Fontan physiology, blood flow 
through the pulmonary arteries is non-pulsatile and largely 
driven by negative intrathoracic pressure and diastolic re-
laxation of the single ventricle. In the absence of pulsatile 
flow, recruitment of pulmonary vessels is reduced, poten-
tially resulting in increased PVR. De Leval suggested that 
the intrinsic lower energy state of the pulmonary circulation 
in the Fontan circuit increases pulmonary vascular imped-
ance and ultimately pulmonary afterload. The West zone 
two, or middle zone of the lungs, is probably smaller in the 
Fontan circulation [31], reducing pulmonary vascular com-
pliance of the Fontan patient. Therefore the Fontan circula-
tion per se promotes an increase in PVR, which can be 
worsen by increased pulmonary lymphatic pressure and 
chronic microembolic events. Pulsatile flow is also important 
in regulating the shear stress-mediated release of a number of 
endothelium-derived vasoactive molecules, and dysregula-
tion of this mechanism may also lead to endothelium dys-
function. A number of endothelium-derived vasoactive fac-
tors have been implicated in the pathophysiology of the en-
dothelial dysfunction characteristic of diseases such as pul-
monary arterial hypertension [32] and their role has been 
investigated as a potential mechanism of increased PVR after 
Fontan completion. The combination of chronic impairment 
in the production of vasoactive mediators, such as endothe-
lium-derived nitric oxide (NO) and prostacyclin, together 
with prolonged overexpression of vasoconstrictors such as 
endothelin 1, leads not only to abnormalities in vascular 
tone, but also to characteristic vascular proliferation and re-
modeling, endothelial dysfunction and associated increases 
in PVR. Studies of expression of these factors suggest that 
Fontan patients do present endothelial dysfunction. Patients 
with failing Fontan have been shown to over-express endo-
thelial-NO synthase relative relative to patients with non-
failing Fontan and normal controls [33]. Endothelin 1 is a 
potent vasoconstrictor with proliferative and hypertrophic 
effects on vascular smooth muscle cells. It appears that endo-
thelin 1 levels are increased in Fontan patients in the acute 
postoperative phase and late after Fontan completion. Plasma 
endothelin levels are elevated in the acute postoperative 
course, and this increase correlate with elevation in PVR and 
central venous pressure early after Fontan completion, never-
theless these effects can be reversed by ultrafiltration. How-
ever, endothelin levels were found to be elevated even late 
after Fontan completion, especially in the proximal intra-
acinar pulmonary arteries of patients with failing Fontan, 
compared with normal controls. Indeed, endothelin-1 single 
nucleotide G5665T polymorphism was found to be associ-
ated with a significant decrease in transplant-free survival for 
palliated single ventricles, with the majority of the decrement 
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  Low cardiac output, excessive hypoxaemia, PLE and 
plastic bronchitis may all be clinical manifestations of in-
creased PVR after Fontan completion. The development of 
pathologies such as protein-dispersion syndromes (protein-
losing enteropathy, plastic bronchitis), aorto-pulmonary col-
laterals or pulmonary AV malformations cannot be fre-
quently explained by hemodynamic pitfalls, and represent 
the most critical complications of the Fontan patient. The 
break in integrity of the enteric mucosal barrier seen in PLE 
affects a number of homeostatic systems [35]. Protein loss 
leads to reduced vascular oncotic pressure with interstitial 
and peripheral edema, ascites, pleural and pericardial effu-
sions; loss of albumin leads to abnormalities in calcium me-
tabolism; loss of coagulation factors further upsets an al-
ready abnormal cascade of coagulation; abnormal flow in 
lymphatic vessels, as a result of lymphatic engorgement, 
may lead to chylothorax, lymphopaenia and a relative immu-
nodeficient state [36]. The pathophysiologic mechanism re-
sulting in PLE is still enigmatic but two issues are believed 
to be involved: lower mesenteric oxygen delivery and in-
flammation. Gastrointestinal perfusion and oxygen delivery 
are reduced after Fontan completion [35]. This is demon-
strated by an increased mesenteric vascular impedance 
measured by Doppler echocardiography in patients with Fon-
tan circulation compared with age-matched normal controls. 
Patients with PLE after Fontan completion present signifi-
cantly higher mesenteric vascular impedance and lower mes-
enteric-to-celiac flow ratio than those without PLE. Moreo-
ver flare of PLE symptoms in Fontan patients frequently 
occurs after acute viral infections, which implies an inflam-
matory mechanism [35,37]. Several studies demonstrated an 
increase in inflammatory markers in PLE, such as TNF-
alpha, C reactive protein, cytokines which seem to play an 
important role in altering intestinal cell membrane perme-
ability to intravascular proteins [20,35].  
  Plastic bronchitis is the other life-threatening complica-
tion of Fontan circulation [38]. Bronchial acellular casts 
forming within the airways can cause obstruction and deter-
mine asphyxiation. Clinical presentation is acute, and physi-
cal findings can dramatically and rapidly worsen. The break 
in integrity of the bronchial mucosa leads to leakage of pro-
teinaceous material into the airways, and is probably secon-
dary to lymphatic engorgement. Unlike PLE, hypoalbu-
minemia and edema may not occur, probably because rela-
tively small amounts of protein are sufficient to cause sig-
nificant airway obstruction. 
  Beyond Fontan fenestration [39,40] or aerosolized tissue 
plasminogen activator [41], lowering PVR even late after 
Fontan completion could prove to be beneficial per se. There 
are few observations describing the effects of PVR lowering 
drugs in the treatment of patients with failing Fontan. Re-
cently Reinhardt [42] and Ozun [43] reported significant 
clinical improvement with the use of pulmonary vasodilators 
in PLE and plastic bronchitis after Fontan completion, there-
fore adding a useful therapeutical implement for failing Fon-
tan circulation. Long-term treatment with bosentan improved 
symptoms, oxygen saturation, functional class, maximal and 
submaximal exercise capacity, Borg dyspnea index, mean 
PAP, pulmonary blood flow and PVR in a patient with plas-
tic bronchitis, as reported by Apostolopuolou et al [44]. The 
effect of sildenafil on exercise-tolerance, ventricular function 
and health-related quality of life in children who have com-
pleted the Fontan procedure is currently under investigation. 
Lowering PVR in patients with failing Fontan circulation 
might be advantageous even as a bridge to heart transplanta-
tion [45], lowering mortality on the waiting list. We specu-
late that conditioning the pulmonary vasculature could be 
beneficial even before Fontan completion, and have success-
fully used pulmonary vasodilators in high-risk second stage 
procedures as well.  
  If medical, surgical and catheter-based interventions are 
unable to improve symptoms, cardiac transplantation repre-
sents the only treatment option for the failed Fontan circula-
tion [8, 9, 12].  
LISTING AND OHT OUTCOME 
 Bernstein  et al [46] reported the outcome of listing for 
cardiac transplantation in 97 patients with failing Fontan 
referred at 17 Pediatric Heart Transplant Study centers in 
North America between 1993 and 2001. Mean age at listing 
was 9.7 years and the mean interval from Fontan completion 
to listing was 4.9 years. However 22% were less than 6 
months after Fontan and 31% less than 1 year, which raises 
the question of poor indication to Fontan completion at first. 
Hazard function and competing outcomes analysis in this 
study suggests that most Fontan patients who die while wait-
ing, will do so in the first 6 months after listing. Survival on 
the waiting list was 78% at 6 months with a 15.5% overall 
mortality rate. Patients who were younger of 4 years of age 
at listing, status 1, patients who had shorter interval since 
Fontan or were ventilator-dependent, were more likely to die 
on the waiting list. Specifically, 33% of patients who were 
less than 6 months from their Fontan died on the waiting list, 
accounting for a dismal 40% survival at 6 months on the 
waiting list for early Fontan failure. Over 50% Fontan pa-
tients listed for OHT were status 1. At 6 months on the wait-
ing list, the probability of receiving a transplant was similar 
for status 1 (65%) and status 2 (68%), however the probabil-
ity of death before a transplant was 22% in status 1 and 5% 
in status 2.  
  Actuarial OHT survival for Fontan diagnosis was 77% at 
1 year and 67% at 5 years, significantly lower compared with 
91% 1-year and 81% 5-year OHT survival for non-
congenital diagnosis. Overall mortality for OHT after Fontan 
failure was 33% . This data suggests that the increased risk 
in Fontan patients is predominantly in the early period after 
transplantation. There was indeed a trend in the Fontan 
group toward a higher rate of early graft failure (17%), infec-
tions (30%) and acute hemorrhage/operative complications 
(9%) as cause of death, compared with other CHD and non-
CHD diagnosis. Early graft failure can be attributable to the 
presence of preformed antibodies (PRA) secondary to use of 
homograft patches and multiple blood transfusions that in-
crease the risk of pre-sensitization, but could also reflect a 
fixed element of PVR that is unmasked with the introduction 
of normal pulmonary blood flow after OHT. It is erroneous 
to assume that because a Fontan patient is alive, the pulmo-
nary vascular resistance is low enough to tolerate a OHT. 
Intolerance to Fontan physiology with prolonged pleural 
effusions, ascites, lymphopenia and protein dispersion can 
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post-OHT immunosuppression. However this study docu-
mented that 73% patients with PLE survived on the waiting 
list for OHT, 76% of those receiving a heart survived after 
OHT with PLE resolution in all OHT survivors.  
 Lamour  et al [47] conducted a study on behalf of the 
Cardiac Transplant Registry Database in association with the 
Pediatric Heart Transplant Study on 488 patients with CHD 
(107 Fontan and 381 non-Fontan) undergoing OHT between 
1993 and 2002. Lamour demonstrated that Fontan patients 
had a 71% 1-year and 60% 5-year OHT-survival, signifi-
cantly lower than 83% 1-year and 74% 5-year OHT-survival 
documented in non-Fontan patients with CHD. Specifically 
having a previous Fontan procedure increased 8.6 times the 
relative risk of death after OHT in this cohort. Conditional 
survival in patients who survived the first 3 months after 
transplant was not different between Fontan patients and 
other non-Fontan CHDs, indicating that the increased risk of 
death is likely related to peri-transplant issues. This study 
suggested that the complexities of OHT after Fontan comple-
tion are not only associated with the technical challenges 
related to the individual anatomy, multiple earlier palliative 
procedures and pulmonary artery distorsion, but also to diffi-
culty in evaluating PVR and an increased propensity for in-
fection and bleeding in Fontan patients. These studies infer 
that OHT in failing Fontan carries substantial early risk, 
higher than in other CHD [48] and even higher than non-
CHD. OHT cannot be considered as a rescue therapy for 
patients who fail the Fontan procedure, neither a viable op-
tion for younger patients who are early Fontan failures. In 
contrast, OHT remains a very good option for older children 
and adolescents who are late Fontan failures.  
  These data are in agreement with our previous report on 
OHT outcome for end-stage CHD. In a cohort of 43 patients 
undergoing OHT for CHD between 1988 and 2002. Mi-
chielon et al [10] verified that single ventricle physiology 
entailed substantial early mortality compared with other 
CHD, accounting for a 67% early OHT-survival in single 
ventricles as opposed to 94% in other CHD. Michielon first 
identified bidirectional Glenn shunting as the best bridge to 
heart transplantation in failing single ventricle physiology 
[12], therefore suggesting OHT as a valid alternative to high-
risk Fontan completion. Indeed OHT transition from a BDG 
stage enabled 100% early and late OHT survival, as opposed 
to 33% early and 5-year survival for OHT after Fontan fail-
ure. This data was noteworthy since it represented a single 
center experience with systematic and uniform approach to 
single ventricle physiology, therefore avoiding the typical 
bias of multi-institutional studies, such as surgical strategy of 
Fontan staging, technique of Fontan completion and referral 
criteria for transplantation. Indeed in our experience Fontan 
completion was systematically prepared by intermediate 
staging with BDG, regardless ventricular morphology, and 
all Fontan completions were accomplished by extracardiac 
technique with conduit interposition between the inferior 
vena cava and the central pulmonary arteries, therefore al-
lowing the best energy preservation pattern of Fontan circu-
lation, as confirmed by physical and mathematical models, 
and the lowest risk of atrial arrhythmias [2]. In other words, 
Fontan failure in this cohort was secondary to predominant 
failure of Fontan physiology, not to untreatable arrhythmias, 
atrial thrombosis or primary ventricular dysfunction. We 
concluded that OHT should be considered in the decision-
making process as an alternative to Fontan completion in 
high-risk candidates, since rescue OHT after failing Fontan 
seemed unwarranted.  
  Jayakumar [21] reported the combined New York, Phila-
delphia and Columbus experience on 35 patients with failing 
single ventricles undergoing OHT between 1984 and 2001. 
Surgical technique of Fontan completion was not elucidated, 
but 57% of patients underwent OHT for ventricular dysfunc-
tion, and only 43% for failed Fontan physiology. The 1-year 
OHT-survival after Fontan completion was 63% as opposed 
to 90% 1-year OHT-survival after Glenn staging. Jayakumar 
stated that this difference in survival was not statistically 
significant, but reported that 9 out of 10 early deaths oc-
curred in the Fontan failure subgroup as opposed to only one 
death for OHT after Glenn shunting. Jayakumar confirmed 
previous reports on high attrition in the early post-OHT pe-
riod for failing Fontans, with over 70% of deaths occurring 
within a week of transplant mainly due to operative hemor-
rhage and infections, therefore underlying the challenging 
technical and immunosuppressive issues involved in this 
subgroup of patients. This data confirmed the experience of 
Michielon et al. with bidirectional Glenn shunting as the best 
bridge to OHT in failing single ventricle physiology [12]. 
 Gamba  et al [9] reported better OHT outcome after fail-
ing Fontan in a cohort of 14 patients undergoing OHT be-
tween 1990 and 2002. Their 1-year OHT survival was 86% 
and the 5-year survival was 77%. However the mean age at 
OHT in this cohort was 17.2 years, and the mean interval 
between Fontan completion and OHT was almost 10 years. 
Therefore this experience mainly refers to OHT for late Fon-
tan failure, which is known to have better overall outcome. 
Indeed most Fontan completion in this cohort were accom-
plished by atriopulmonary connections, and single ventricle 
dysfunction, arrhythmias and atrial thrombosis represented 
the most common indication for OHT (57%). Nevertheless 
this report confirmed the benefit of OHT on PLE recovery, 
although a 5-year mean follow-up does not allow for conclu-
sive statements. 
  These reports suggest that the modes of presentation for 
the failed Fontan Fontan circulation is twofold: failed Fontan 
physiology and ventricular dysfunction. Failed Fontan 
physiology, such as refractory ascites, pleural effusions, 
PLE, plastic bronchitis may occur in the setting of relatively 
preserved ventricular function. Characterization of ventricu-
lar function in patients with indeterminate or right dominant 
ventricular morphology is largely subjective and measure-
ment of the end-diastolic pressure in underloaded ventricles 
with low-output and poor transit of systemic venous blood 
through the lungs may be misleading. Based on these find-
ings, Griffiths and Del Nido [49] identified the indication to 
OHT performed at CHB between 1994 and 2008 in failed 
Fontan with impaired ventricular function versus patients 
with preserved ventricular function but failed Fontan physi-
ology. PLE or plastic bronchitis were present in over 80% 
patients with preserved ventricular function and in no pa-
tients with impaired ventricular function group. The im-
paired ventricular function group had significantly lower 
cardiac index, SvO2 and significantly higher SVR compared 
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ial survival after OHT was 88.9% in impaired ventricular 
function vs 56.2% in preserved ventricular function. One 
year survival in preserved ventricular function was similar to 
one year survival in non transplanted patients, raising the 
question of the efficacy of OHT in this subgroup of patients.  
  Improvements in OHT survival according to year of 
transplant have been reported by most centers as well as by 
the Registry of the International Society for Heart and Lung 
Transplantation [10, 11, 21, 48]. There continues to be a 
small trend towards an increasing number of pediatric heart 
transplants reported to the Registry, from an annual average 
of 384 transplants in the 1990’s, to 428 in the 2000’s to 491 
in 2008. Earlier year of transplant was found to be a signifi-
cant risk factor for mortality. This finding is mirrored in the 
overall experience of OHT for CHD [10, 48] and OHT for 
failed single ventricle physiology as well. Jayakumar [21] 
reported a 64% 5-year OHT-survival for failing single ven-
tricles transplanted before 1995, and a 77% 5-year OHT-
survival for transplants performed between 1996 and 2001. 
We report an 8-year survival of 79.6% in 25 patients under-
going OHT for failing single ventricles between 2003 and 
2010. The 5-year survival for OHT in failing Fontan was 
66%. These results compare favorably with our previous 
33% 1-year survival for failing Fontans undergoing OHT 
before 2002. Ventricular dysfunction was the dominant 
mechanism of late extracardiac Fontan failure (80% pa-
tients), while early Fontan failure was mainly due to failing 
Fontan physiology in the setting of relatively preserved ven-
tricular function (80% patients). Fontan status remained a 
risk factor of mortality after OHT while bidirectional Glenn 
staging was confirmed as the best bridge to heart transplant, 
with 100% 5-year survival after OHT, even in our most re-
cent experience. Early Fontan failure represented the only 
independent predictor of mortality after OHT, with and odds 
ratio of 13.1 and a dismal 20% 1-year survival, while excel-
lent outcome (90% 5-year survival) can be expected in OHT 
candidates for late Fontan failure without significant end-
stage comorbidities (hepatic cirrhosis, chronic malnutrition).  
  BDG is therefore advocated as the best bridge to OHT, 
while early Fontan failure is mostly associated with failure of 
Fontan physiology, which renders rescue OHT outcome un-
warranted. We could speculate that Fontan take-down in 
early Fontan failure could not only improve overall survival 
but also OHT outcome. Take-down Fontan should theoreti-
cally decompress the splanchnic venous congestion assuring 
optimal ventricular filling and cardiac output, at the expense 
of systemic oxygen desaturation. Down-staging to bidirec-
tional Glenn should reproduce the excellent results of OHT 
after BDG. However this issue is not straightforward. The 
overall experience with Fontan takedown has been discour-
aging, with an early mortality rate approaching 50%. Knott-
Craig reported [50] a 62.5% mortality rate after early Fontan 
take-down on over 700 modified Fontan operations per-
formed at the Mayo Clinic over a 16-year interval. A more 
recent experience of the Boston’s Children group reported a 
45% mortality rate in 53 Fontan take-downs performed be-
tween 1979 and 2006 [51]. Take-down performed within a 
month from Fontan completion (acute take-down) was asso-
ciated with highest mortality rate (51%). Indeed Almond 
[51] retrospectively verified the presence of correctable ab-
normalities in 44% of early Fontan failures. Therefore out of 
the 29 take-down survivors, only 3 patients underwent OHT 
within 14 years from Fontan take-down, with no early mor-
tality. We believe that early Fontan take-down remains the 
only life-saving surgical option for early Fontan failure, but 
in our limited experience we could not demonstrate a defini-
tive advantage of take-down for early Fontan failure on im-
mediate post-OHT outcome, and verified a 50% mortality in 
rescue OHT after Fontan take-down.  
  In conclusion, OHT is an effective therapy for failing 
single ventricles. OHT outcome has improved in recent 
years, with an expected 5-year survival approaching 80% in 
the overall experience with failing single ventricles. Fontan 
status remains a risk factor of mortality after OHT with an 
expected 5-year survival barely approaching 70%, partially 
related to the evidence of pulmonary vascular disease after 
OHT for Fontan circulation failure [52]. The attrition is 
highest in OHT after early Fontan failure, with a 50% 1-year 
survival in the best reported series. Mortality frequently oc-
curs in the early post-OHT period, for predominant infective 
complications. Tailoring of immunosuppressive therapy is a 
crucial issue in these patients since they are immunocom-
promized for their Fontan failure. Pre-sensitization for previ-
ous blood transfusions and liberal use of homograft material 
is very common [53], puzzling the balance between immu-
nosuppression and risk of life threatening infections. Excel-
lent OHT outcome and 90% one-year survival is predicted 
for late Fontan failures, with predominant ventricular dys-
function and without significant comorbidities such as he-
patic cirrhosis or chronic malnutrition. PLE is a catastrophic 
complication of Fontan completion, but can be improved by 
OHT [9,21,54,55], although mortality on the waiting list can 
be as high as 40%. Moreover long-term fate of PLE after 
OHT has not been completely elucidated, and recurrence of 
PLE even after OHT has been reported. Early diagnosis of 
other life-threatening Fontan complications, such as plastic 
bronchitis, is crucial to allow for effective medical therapy, 
by a combination of potent pulmonary vasodilator and fibri-
nolitic agents [41-45] and early referral for OHT. Bidirec-
tional Glenn staging currently represents the best bridge to 
heart transplant in failing single ventricles, but Fontan take-
down and down-staging to BDG does not warrant compara-
ble OHT outcome as BDG at first. This caveat underlines the 
critical point of optimal referral criteria for both Fontan 
completion and OHT in single ventricle physiology. OHT 
should be considered as an alternative to Fontan completion 
in the decision-making algorithm for high-risk Fontan candi-
dates, since rescue OHT after early Fontan failure is unwar-
ranted. In the near future, incorporation of a mechanical as-
sist device such as an axial flow pump in the Fontan circula-
tion may prove to be beneficial, either as a bridge to recov-
ery, possibly converting the high risk patient into a relatively 
good candidate for the Fontan circulation, or as a bridge to 
transplant, therefore reducing attrition on the transplant list 
and bridging the worse patients to successful heart transplan-
tation.  
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